Option chain shows key data for Helius Medical Tech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Helius Medical Tech.

Helius Medical Tech (NASDAQ:HSDT) Stock, Option Chain

Helius Medical Tech

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

Pinterest Inc.

AFRM

BILL

CVRX

DOCS

FARM

FCAP

FTLF

HSDT

MGOL

MPWR

NIVF

NKLA

PINS

RAMP

TMCI

Why Pinterest Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

King,County,,Washington,,United,States,-,30,January,2022:,Netflix

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ANAB

ASST

CCLD

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

DWTX

HUBC

LSTA

NEHC

NFLX

SEPN

STFS

USEG

Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

wall street chart shutter2

Equities

Eurozone

Commodities

Intraday Update

New Oriental Education & Technology Group

EOLS

FTAI

GOEV

REPL

SCHW

Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates

Helius Medical Technologies, Inc. - Class A Common Stock

Helius Medical Technologies Inc

Helius Medical Technologies Inc Warrants (02/02/2026)

U.S. President Donald Trump has terminated an oil agreement with Venezuela, revoking a license previously granted to&nbsp;Chevron Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) by former President Joe Biden.
What Happened: Trump took to his Truth Social to announce the cancellation of Chevron&#8217;s Venezuela operations on Wednesday. This was based on the lack of progress on electoral reforms and migrant returns by Venezuelan President Nicolas Maduro. Though Trump did not mention Chevron in his post, the date mentioned, i.e, November 26, 2022, was when the oil giant was given the license to operate in Venezuela&#8217;s oil sector. However, Trump did not mention the details of &#8220;electoral conditions.&#8221;
Chevron did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment. 
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="612" height="412" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27034654/Screenshot-2025-02-27-141557.png" alt="" class="wp-image-801056" style="width:658px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27034654/Screenshot-2025-02-27-141557.png 612w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27034654/Screenshot-2025-02-27-141557-300x202.png 300w" sizes="(max-width: 612px) 100vw, 612px" /></figure>
The decision was met with disapproval from Delcy Rodriguez, Venezuelan Vice President, who deemed it a &#8220;damaging and inexplicable decision,&#8221; reported Reuters. Nevertheless, Marco Rubio, the U.S. Secretary of State defended the move, arguing it was designed to end all oil and gas licenses from the Biden-era that have &#8220;shamefully bankrolled the illegitimate Maduro regime.&#8221;
Chevron, which exports approximately 240,000 barrels of crude daily from its Venezuela operations, stated it has knowledge of Trump&#8217;s stance and was evaluating the implications of his decision. The termination of the license means that Chevron will no longer be permitted to export Venezuelan crude.
Since his January return to office, Trump has consistently stated that the U.S. does not require Venezuelan oil and hinted at the potential revocation of Chevron&#8217;s operating license. Trump announced that the oil concession agreement will be terminated effective March 1, instead of being renewed.
SEE ALSO: <a href="https://www.benzinga.com/news/25/02/43999592/mark-cuban-offers-support-to-elon-musk-but-only-if-tesla-ceo-backs-ro-khannas-anti-lobbying-bill">Mark Cuban Offers Support To Elon Musk—But Only If Tesla CEO Backs Ro Khanna&#8217;s Anti-Lobbying Bill</a>
Why It Matters: Chevron played a pivotal role in driving the growth of oil production and the economy in Venezuela. A Bloomberg report in January highlighted that Chevron submitted tax returns totaling approximately $300 million to the Venezuelan government last year, sparking concerns about the extent to which President Nicolás Maduro is profiting from the U.S. oil giant&#8217;s production despite sanctions.
Meanwhile, David Goldwyn, head of the energy advisory group at the Atlantic Council, previously told Bloomberg, "Chevron's activity in Venezuela is in both country's interests, as it's having an efficient player helping the Venezuela economy from falling back and preventing migrants from coming back." This is particularly notable as Trump has expressed discontent over the slow progress of the return of Venezuelan migrants back to their country. 
Oil prices inched higher on Thursday following declines in the past two sessions, as supply concerns re-emerged after Trump revoked Chevron&#8217;s license to operate in Venezuela. At 07:31 GMT, Brent crude futures had risen by 2 cents to $72.55 per barrel, while U.S. West Texas Intermediate (WTI) crude futures increased by 6 cents to $68.68 per barrel.
This decision comes on the heels of <a href="https://www.benzinga.com/markets/25/02/43685595/chevron-announces-about-20-workforce-reduction-in-cost-saving-initiative-responsible-leadership-requires-taking-these-steps">Chevron&#8217;s recent announcement</a> of a significant workforce reduction. Chevron planned to cut its workforce by up to 20% as part of a broader cost-saving initiative. The company aimed to reduce costs by $2 billion to $3 billion by the end of 2026. The termination of the Venezuelan license could potentially impact these cost-saving measures.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43990066/bitcoin-ethereum-xrp-dogecoin-extend-decline-btc-at-80000-by-mid-april-trader-wonders">Bitcoin, Ethereum, XRP, Dogecoin Extend Decline: &#8216;BTC At $80,000 By Mid-April?,&#8217; Trader Wonders</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump Shuts Down Chevron's Venezuela Oil Permit, Tightening Pressure On Maduro Regime: Crude Oil Prices Rise On Supply Concerns

https://www.reuters.com/business/finance/hsbc-cutting-staff-numbers-by-900-china-pinnacle-unit-sources-say-2025-02-27/#:~:text=HONG%20KONG%2C%20Feb%2027%20(Reuters,expansion%20plans%20in%20that%20country.

HSBC

Reuters Reported HSBC Cutting ~900 Jobs At China Digital Wealth Unit Pinnacle

CEVA

Ceva Launches Latest High-performance, Baseband Vector DSPs Targeting Advanced 5G And 6G-Ready Applications

Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $64 price target.

Price Target

Reiteration

Analyst Ratings

RYTM

Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $64 Price Target

RTX Says Pratt & Whitney GTF Advantage Engine Has Achieved US FAA Type Certification For Airbus A320neo Family

Gladstone Investment Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIN#NASDAQ">GAIN</a>) ("Gladstone Investment") continued its support of portfolio company Pyrotek Special Effects, Inc. ("Pyrotek") through providing additional capital to support the acquisition of Unique Pyrotechnic ("Unique").

Tech

GAIN

INTC

MSFT

NVDA

Wall Street Journal Reported Microsoft Urges Trump Administration To Lift AI Chip Export Limits for Allies, Calls For Simplified Control Rules

Needham analyst Mike Matson maintains Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Buy and lowers the price target from $65 to $64.

ENOV

Needham Maintains Buy on Enovis, Lowers Price Target to $64

Financial analyst Jim Cramer called Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) a "misunderstood" stock on Wednesday, seeing it as an investment in the future of investing
What happened: In an X post, Cramer emphasized that Robinhood is not merely a play on cryptocurrencies or risky options.
"It is an investment in the way the next generations will invest, and it has the field to itself because most investment houses don&#8217;t even want their clients and don&#8217;t understand what they want," the host of CNBC's popular Mad Money show said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Robinhood is NOT a play on crypto or dangerous options. It is an investment in the way the next generations will invest and it has the field to itself because most investment houses don&#39;t even want their clients and don&#39;t understand what they want. Big mistake
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1894697143530660076?ref_src=twsrc%5Etfw">February 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
In a separate post, Cramer deemed Robinhood a "very misunderstood" company. He believed Robinhood was creating platforms that simplify market navigation for its customers.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Robinhood is very misunderstood company and stock. .The company is designing sites that make it easier for its customers to negotiate the markets the way they want to.
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1894696779825713647?ref_src=twsrc%5Etfw">February 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Robinhood is a mobile-based, commission-free trading platform that allows users to buy and sell stocks, exchange-traded funds, options, and cryptocurrencies, including Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>).&nbsp;
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43996312/sec-closes-investigation-against-crypto-exchange-gemini-says-cameron-winklevoss-another-milestone-to-the-end-of-the-war-on-crypto">SEC Closes Investigation Against Crypto Exchange Gemini, Says Cameron Winklevoss: &#8216;Another Milestone To The End Of The War On Crypto&#8217;</a>
Why It Matters: Cramer&#8217;s views come in the wake of Robinhood CEO Vlad Tenev's <a href="https://in.benzinga.com/markets/cryptocurrency/25/02/43980238/robinhood-ceo-tenev-remains-upbeat-the-business-has-been-doing-tremendously-well">optimism about the company&#8217;s future</a> and the broader cryptocurrency landscape.&nbsp;
Tenev highlighted the firm&#8217;s strong performance, including its first billion-dollar revenue quarter and record net income profits. The company also <a href="https://in.benzinga.com/markets/cryptocurrency/25/02/43682382/robinhood-ceo-vlad-tenev-reveals-what-hes-most-excited-about-as-crypto-revenue-skyrockets-8x-stock-surges-15-after-hours">reported a fivefold jump</a> in cryptocurrency volumes in the fourth quarter.
More importantly, the SEC <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43914267/sec-drops-investigation-into-robinhoods-crypto-unit">ended its investigation</a> of the firm's cryptocurrency operations without pursuing any enforcement action.
Price Action: Shares of Robinhood were up 3.42% in after-hours trading, after closing 6.38% higher at $48.85, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. 
As is well known, the "Inverse Cramer" phenomenon hinges on the belief that doing the opposite of what Cramer advises could lead to profits. There has been no definitive proof, though, of counter-trading Cramer's predictions being a profitable strategy.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/02/43997635/bitcoin-spin-off-litecoin-ethereum-killer-avalanche-weather-crypto-meltdown-heres-why-ltc-avax-are-spiking">Bitcoin Spin-Off Litecoin, &#8216;Ethereum Killer&#8217; Avalanche Weather Crypto Meltdown, Here&#8217;s Why LTC, AVAX Are Spiking</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" rel="noreferrer noopener" target="_blank"></a>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

HOOD

Jim Cramer Says 'Misunderstood' Robinhood Stock Not Merely A Crypto Play: 'It's An Investment In The Way The Next Generations Will Invest'

Outlook and guidance
The Company expects to produce approximately 25,000MT to 28,000MT of polysilicon during the first quarter of 2025. The Company expects to produce approximately 110,000MT to 140,000MT of polysilicon for the full year of 2025, inclusive of the impact of the Company's annual facility maintenance.

Earnings

Guidance

Daqo New Energy Expects Q1 Polysilicon Output Of 25,000MT–28,000MT And Full-Year Forecast 110,000MT–140,000MT

Daqo New Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) reported quarterly losses of $(2.56) per share which missed the analyst consensus estimate of $(2.08) by 23.08 percent. This is a 372.34 percent decrease over earnings of $0.94 per share from the same period last year. The company reported quarterly sales of $195.36 million which beat the analyst consensus estimate of $153.54 million by 27.23 percent. This is a 59.06 percent decrease over sales of $477.13 million the same period last year.

Earnings Beats

Earnings Misses

Daqo New Energy Q4 2024 Adj EPS $(2.56) Misses $(2.08) Estimate, Sales $195.36M Beat $153.54M Estimate

Needham analyst Gil Blum reiterates Immunocore Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) with a Buy and maintains $71 price target.

IMCR

Needham Reiterates Buy on Immunocore Hldgs, Maintains $71 Price Target

Needham analyst Serge Belanger maintains MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and raises the price target from $62 to $66.

MLTX

Needham Maintains Buy on MoonLake, Raises Price Target to $66

Needham analyst Gil Blum maintains Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) with a Buy and lowers the price target from $7 to $5.

GERN

Needham Maintains Buy on Geron, Lowers Price Target to $5

Needham analyst David Saxon maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and raises the price target from $106 to $107.

Needham Maintains Buy on Alcon, Raises Price Target to $107

Haleon Sees FY25 Organic Revenue Growth Of 4%-6%, Allocates GBP500M For Share Buybacks

Haleon FY Adjusted EPS GBp17.9 Up From GBp17.3 YoY, Sales GBP11.2B Down From GBP11.3B YoY

This underlines Expro as a preferred partner for well construction services in CCS, highlighting the company's technical expertise and innovation.

Contracts

XPRO

Expro Secures Contract For Netherlands' First Offshore Carbon Capture Project, Advancing Sustainable Well Construction

The agreement will see around 90% of Austrian credit institutions move their regulatory reporting infrastructure to the cloud, upgrading their legacy on-premises solution to Nasdaq AxiomSL. It reflects the growing demand for regulatory technology solutions that simplify banks' underlying architecture to more flexibly meet future requirements.

NDAQ

Nasdaq Secures Deal With AuRep To Modernize Austria's Regulatory Reporting, Powering Cloud Transformation For 90% Of Credit Institutions

Six Flags Entertainment Sees FY25 Adj EBITDA Of $1.08B - $1.12B

Cedar Fair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>) reported quarterly losses of $(2.76) per share which missed the analyst consensus estimate of $0.32 by 962.5 percent. This is a 1352.63 percent decrease over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $687.31 million which missed the analyst consensus estimate of $700.52 million by 1.89 percent. This is a 85.20 percent increase over sales of $371.12 million the same period last year.

Cedar Fair Q4 EPS $(2.76) Misses $0.32 Estimate, Sales $687.31M Miss $700.52M Estimate

Press Releases

Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study

Health Care

General

Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece

Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference

Helius Medical Technologies, Inc. Announces Exploration of Strategic Alternatives

Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device

Helius Announces First Portable Neuromodulation Stimulator (PoNS®) System Sale to the Veterans Affairs (VA) Healthcare System

Helius Medical Technologies, Inc. Announces Strong Enrollment of its Stroke Pivotal Study Exceeding Initial Target

Helius Medical Technologies, Inc. Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $3.7 Million Gross Proceeds Priced At-the-Market

Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study

Comments

Helius Medical Tech

Helius Medical Tech (HSDT) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga